Tiludronate and Clodronate do not Affect Bone Structure or Remodeling Kinetics over a 60 Day Randomized Trial - Dataset

Tiludronate (TIL) and clodronate (CLO) are FDA-approved bisphosphonate drug therapies for navicular disease in horses. Although clinical studies have determined their ability to reduce lameness in horses, data regarding the effect on bone structure and remodeling is lacking. Additionally, due to off-label use of these drugs in young performance horses, effects on bone in young horses need to be investigated. Therefore, the purpose of this randomized, experimental pilot study was to determine the effect of TIL and CLO on normal bone cells, structure and remodeling after 60 days in clinically normal, young horses. Additionally, the effect of CLO on bone healing 60 days after an induced defect was investigated. Data included are raw micro-computed tomography data, and static and dynamic histomorphometry data from all horses analyzed. Abbreviations, formulas, and units are standard for the field and are referenced within the published article.